STEM CELL THERAPEUTIC

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelerating North American Launch of CARTISTEM®

MEDIPOST Completes Administration for Phase 3 Clinical Trial of CARTISTEM® for Knee Osteoarthritis in Japan

MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opportunities at Global Bio-Pharma Events in US and Japan

MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 Patients

MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®

MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal

MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan

MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award

MEDIPOST gears up to enter the global SMUP-IA-01 market based on clinical results in Korea

MEDIPOST’s treatment for knee osteoarthritis, enters phase 3 clinical trials in Japan

MEDIPOST’s injectable drug for knee osteoarthritis, SMUP-IA-01, enters phase 2 clinical trials in Korea

MEDIPOST receives approval to proceed with phase 2 clinical trial in Korea for its next-generation injectable drug for knee osteoarthritis, SMUP-IA-01